About Kisspeptin Reviews

What this site is

Kisspeptin Reviews is an independent editorial project that publishes summaries of the peer-reviewed research literature on kisspeptin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site reviews the peer-reviewed record systematically. Every quantitative claim — dose values, half-life figures, trial outcomes, study counts — is traced to a registered clinical trial, a peer-reviewed journal article, or a published systematic review. No claim is sourced to anecdotal reports, vendor literature, or unregistered personal testimonials. Where the evidence is limited or contested, the text says so.

The 'Reviews' modifier in the domain name refers to institutional reviews of the research record — reading across 15+ randomized controlled trials from a single research group and presenting what they show — not to user-generated product reviews or commercial ratings.

Editorial standards

The site's content is organized around the following principles:

Source quality. Primary sources are peer-reviewed publications in indexed journals (PubMed, PubMed Central) and registered clinical trials (ClinicalTrials.gov). Reviews and systematic reviews from the same indexed databases are used where they synthesize primary data. No secondary or tertiary sources that are not themselves published under peer-review are cited.

Accurate framing. The site uses consistent third-person, study-attributed language: 'in the Jayasena 2014 trial, researchers observed...', 'animal model studies found...', 'a 2025 systematic review concluded...'. Kisspeptin is described as investigational, not approved, for any human use. Dosing information is presented as administration parameters from registered protocols — not as recommendations.

No prescriptive content. The site does not recommend doses, frequency, or routes of administration for any use case. It describes what registered clinical trials administered, in what context, and what they observed. These are different things.

Currency. Where 2024 and 2025 publications are available, they are incorporated. The kisspeptin research field is active — the 2025 intranasal delivery paper (eBioMedicine) and the 2025 safety RCT (n=95, JCEM) represent the most recent published data as of the writing of this site.

No commercial relationships. Kisspeptin Reviews has no commercial relationship with any research peptide vendor, clinic, pharmacy, or drug developer. No affiliate links, no sponsored content, no product placements appear on this site.

About the compound

Kisspeptin is an endogenous neuropeptide — produced naturally by the human body — whose central role in reproductive axis activation has been established through 20 years of genetic, animal model, and human clinical research. It is not a synthetic analog, a modified compound, or a small-molecule pharmaceutical. The kisspeptin studied in clinical trials is a sequence-identical peptide synthesized for research use.

The compound is not approved by the FDA, EMA, or any major regulatory agency for any therapeutic indication. It is classified as investigational. All the human clinical data reviewed on this site derives from registered trials conducted under ethical oversight at academic institutions, most prominently the Imperial College London Reproductive and Investigative Endocrinology Group led by Professor Waljit Dhillo.

This site does not sell kisspeptin or facilitate its procurement. The disclaimer below applies to all content on this site.